Mind over matter - partnerships: CNS deals signed over the past five years
This article was originally published in Scrip
Executive Summary
Attention deficit hyperactivity disorder (ADHD)
Date
Company
Partner
Deal terms
March 2009
GlaxoSmithKline
Shire
co-promotion of Shire's Vyvanse (lisdexamfetamine dimesylate) for the treatment of attention deficit hyperactivity disorder in the US
November 2008
GlaxoSmithKline
Paladin Labs
three-year contract giving Paladin exclusive distribution rights for GSK's Dexedrine (dextroamphetamine sulfate) for the treatment of ADHD and in the adjunctive treatment of narcolepsy, in Canada